Clinical Trials on CNS Malignancies in Portugal

Total 80 results

Novartis Pharmaceuticals

Recruiting

Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study

Relapsing Multiple Sclerosis

Portugal
Bayer

Completed

Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors (POR-BetaPlus)

Secondary Progressive Multiple Sclerosis (SPMS) | Relapsing Remitting Multiple Sclerosis (RRMS)

Portugal
Memorial Sloan Kettering Cancer Center
University of Pisa; University of California, San Francisco; The Champalimaud...

Active, not recruiting

Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy

Melanoma | Sarcoma | Ovarian Cancer | Bone | Soft Tissue | Lymph Nodes | CNS-Spinal CD/MEMBR, NOS

United States, Italy, Portugal
Bayer

Completed

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis (CogniPlus)

Multiple Sclerosis

Turkey, Czechia, Hungary, Israel, Germany, France, Belgium, Greece, Netherlands, Egypt, Kazakhstan, Argentina, Portugal, Algeria, Saudi Arabia, Albania, Tunisia
Pfizer

Terminated

A Study Of Early Markers Of Choroidal Neovascularization

Age-related Macular Degeneration (AMD) | Choroidal Neovascularization (CNV) | Early Markers

Italy, Portugal, United Kingdom
Biogen

Completed

Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy (PLENO)

Relapsing Remitting Multiple Sclerosis

Portugal
Kiadis Pharma

Completed

Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

Canada, Belgium, Germany, Croatia, United Kingdom, Portugal
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Recruiting

Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)

Multiple Sclerosis

Greece, Czechia, Portugal, Belgium, Netherlands, Poland
Bayer

Completed

BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program

Relapsing Remitting MS (RRMS) | Secondary Progressive MS (SPMS)

France, Germany, Korea, Republic of, Saudi Arabia, Spain, Taiwan, Czech Republic, Italy, Jordan, Lebanon, Turkey, Israel, Portugal, Netherlands, Iran, Islamic Republic of
Biogen

Completed

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants (TYPIFI)

Relapsing Remitting Multiple Sclerosis

Portugal
Genzyme, a Sanofi Company

Active, not recruiting

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT (LemKids)

Multiple Sclerosis

Portugal, Turkey, Italy, Austria, Belgium, France, Netherlands, Poland, Russian Federation, United Kingdom
Novartis

Completed

Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis

Multiple Sclerosis

Switzerland, Germany, Spain, Portugal, Canada, Denmark, Finland, France, Italy, Poland, United Kingdom
Bayer

Completed

Physical Activity and Fatigue in Early Multiple Sclerosis (MS) (BEGIN)

Multiple Sclerosis

Switzerland, France, Germany, Indonesia, Korea, Republic of, Spain, Sweden, Thailand, Taiwan, Australia, Austria, Colombia, Czech Republic, Italy, Jordan, Kazakhstan, Lebanon, Mexico, Slovenia, United Kingdom, Bahrain, Egypt, United... and more
Hoffmann-La Roche

Recruiting

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous RO7121932 in Participants With Multiple Sclerosis.

Multiple Sclerosis

United States, Italy, Germany, Poland, Belgium, Canada, Israel, Portugal, Moldova, Republic of, Romania
Merck Sharp & Dohme LLC

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid Tumors | Hematologic Malignancies

United States, Poland, Brazil, Ukraine, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic... and more
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
Merck Hellas sa., Greece, an affiliate of Merck KGaA, Darmstadt, Germany

Active, not recruiting

Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)

Multiple Sclerosis

Greece, Switzerland, Norway, Italy, Poland, Portugal
Sanofi

Completed

Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis (TEMSO)

Multiple Sclerosis

Ukraine, Russian Federation, Estonia, Czech Republic, Denmark, Finland, France, Turkey, United Kingdom, United States, Portugal, Austria, Canada, Chile, Germany, Italy, Netherlands, Norway, Poland, Sweden, Switzerland
Novartis Pharmaceuticals

Completed

Long-term Follow-up of Fingolimod Phase II Study Patients (ACROSS)

Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis

Spain, Canada, France, Switzerland, Italy, Portugal, Denmark, Poland, Germany, United Kingdom
Allergan

Completed

Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)

Multiple Sclerosis | Urinary Incontinence | Neurogenic Bladder

France, Poland, Portugal, Belgium, Canada, Russian Federation, Czechia, United States
Bayer

Completed

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment (BEACON)

Relapsing Remitting Multiple Sclerosis (RRMS)

China, Slovakia, France, Germany, Korea, Republic of, Saudi Arabia, Singapore, Sweden, Taiwan, Colombia, Czech Republic, Estonia, Italy, Jordan, Lebanon, Mexico, Slovenia, United Kingdom, Argentina, Bahrain, Egypt, United Arab Emirates and more
Merck KGaA, Darmstadt, Germany

Completed

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR)

Relapsing-Remitting Multiple Sclerosis

Germany, Estonia, Latvia, Lithuania, Finland, Austria, Denmark, Netherlands, Portugal, Switzerland, Norway, Italy
Genzyme, a Sanofi Company

Active, not recruiting

Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis (TERIKIDS)

Multiple Sclerosis

Belgium, United States, Bulgaria, Canada, China, Estonia, France, Greece, Israel, Lebanon, Lithuania, Morocco, Netherlands, Portugal, Russian Federation, Serbia, Spain, Tunisia, Turkey, Ukraine, United Kingdom
Bayer

Completed

BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies

Multiple Sclerosis

Spain, Belgium, Czechia, Italy, United Kingdom, Hungary, Germany, Switzerland, Austria, France, Poland, Canada, Sweden, Finland, Israel, Denmark, Norway, Portugal
Biogen

Completed

Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™. (PERSIST)

Multiple Sclerosis

Sweden, France, United Kingdom, Germany, Denmark, Netherlands, Slovakia, Switzerland, Norway, Portugal
Merck KGaA, Darmstadt, Germany

Completed

REbif FLEXible Dosing in Early Multiple Sclerosis (MS) (REFLEX)

Multiple Sclerosis

Croatia, Bulgaria, France, Italy, Russian Federation, Spain, Turkey, Estonia, Germany, Latvia, Poland, Romania, Argentina, Israel, Portugal, Greece, Czech Republic, Slovakia, Serbia, Austria, Finland, Saudi Arabia, Belgium, Canada, Lebanon and more
Merck KGaA, Darmstadt, Germany

Completed

Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX) (REFLEXION)

Multiple Sclerosis | Clinically Isolated Syndrome

Croatia, Bulgaria, France, Italy, Russian Federation, Spain, Estonia, Germany, Latvia, Poland, Romania, Argentina, Finland, Israel, Greece, Czech Republic, Slovakia, Austria, Belgium, Canada, Lebanon, Morocco, Portugal, Serbia
Bayer

Completed

Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis

Multiple Sclerosis

Belgium, Italy, Spain, France, Switzerland, Israel, Czech Republic, Canada, Austria, Poland, Germany, Netherlands, United Kingdom, Hungary, Portugal, Finland, Norway, Sweden, Slovenia, Denmark
Novartis Pharmaceuticals

Recruiting

The Gilenya Pregnancy Registry

Multiple Sclerosis

Denmark, Spain, Switzerland, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Cyprus, Czechia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Mexico, Netherlands, Norway, Poland, ... and more
Bayer

Completed

BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study

Multiple Sclerosis

Belgium, Italy, Spain, France, Germany, Canada, Switzerland, Austria, Denmark, Hungary, Netherlands, Poland, Israel, United Kingdom, Finland, Sweden, Norway, Czech Republic, Portugal, Slovenia
Actelion

Terminated

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) (POINT)

Multiple Sclerosis

United States, Germany, Hungary, Poland, United Kingdom, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, France, Greece, Italy, Mexico, Portugal, Russian Federation, Spain, Switzerland
Sanofi

Completed

Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

United States, Austria, Canada, Chile, Czech Republic, Denmark, Estonia, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Sweden, Switzerland, Turkey, Ukraine, United Kingdom
Biogen

Completed

Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis (ENABLE)

Multiple Sclerosis

France, Italy, United Kingdom, Germany, Australia, Belgium, Netherlands, Portugal, Denmark
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)

Multiple Sclerosis (MS)

United States, Lebanon, Spain, Sweden, Poland, Italy, Estonia, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Finland, France, Georgia, Germany, Korea, Republic of, Lithuania, Norway, Portugal, Romania, Russian Federation and more
Celgene

Completed

A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

Multiple Sclerosis

United States, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Georgia, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Moldova, Republic of, New Zealand, Poland, Portugal, Romania, Serbia, Slovakia, South... and more
Actelion

Completed

Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis (OPTIMUM-LT)

Multiple Sclerosis

United States, Spain, Hungary, Israel, Portugal, Germany, Russian Federation, Belarus, Poland, Serbia, Latvia, Turkey, Croatia, Canada, Czechia, Bulgaria, Bosnia and Herzegovina, Finland, France, Georgia, Greece, Italy, Lithuania, Mexico and more
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Multiple Sclerosis

United States, Argentina, Poland, Canada, Australia, Belgium, Brazil, Denmark, France, Germany, Greece, Hungary, Italy, Peru, Portugal, Russian Federation, Spain, Switzerland, Turkey, Ukraine, United Kingdom
Biogen

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Spain, Germany, Croatia, Turkey, Saudi Arabia, Hungary, Belgium, Australia, France, Portugal, Slovakia, United States, Bulgaria, Greece, Kuwait, Russian Federation, Tunisia, Italy, Argentina, Czechia, Israel, Serbia
Merck KGaA, Darmstadt, Germany

Completed

Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)

Multiple Sclerosis

Hungary, Belgium, Portugal, Slovakia, France, Finland, Poland, Denmark, Czechia, Spain, United Kingdom, Italy, Austria, Greece, Lithuania, Netherlands, Norway, Sweden
Biogen

Completed

An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice (LIBERATE)

Multiple Sclerosis

France, Spain, Germany, Netherlands, Argentina, Czechia, Israel, Portugal, United Arab Emirates, Canada, Norway, Lebanon, Ireland
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Multiple Sclerosis (MS)

United States, Belgium, Spain, Taiwan, Italy, Germany, Canada, Estonia, Mexico, Croatia, Slovakia, Turkey, India, Argentina, France, Israel, Australia, Austria, Serbia, Brazil, Guatemala, Latvia, Poland, Portugal, Russian Federation, Romania and more
Actelion

Completed

Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis (OPTIMUM)

Multiple Sclerosis

United States, Belarus, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Finland, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Latvia, Lithuania, Mexico, Poland, Portugal, Romania, Russian Federation, Serbia, S... and more
Hoffmann-La Roche

Active, not recruiting

This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

Multiple Sclerosis

Canada, United Kingdom, Belgium, Brazil, Croatia, Mexico, Slovakia, Ireland, Netherlands, Estonia, Norway, Denmark, Italy, Poland, Spain, Bulgaria, France, Turkey, Portugal, Sweden, Argentina, Kuwait, Slovenia, Czechia, Hungary, Finland
EMD Serono Research & Development Institute, Inc.

Completed

Oral Cladribine in Early Multiple Sclerosis (MS) (ORACLE MS)

Multiple Sclerosis

Lebanon, United States, Turkey, Sweden, Finland, France, Thailand, Serbia, Italy, United Kingdom, United Arab Emirates, Bulgaria, Belgium, Estonia, Argentina, Austria, Bosnia and Herzegovina, Canada, Croatia, Czechia, Georgia, Ger... and more
Celgene

Completed

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) (SUNBEAM)

Multiple Sclerosis

United States, Spain, Czechia, Russian Federation, Portugal, Serbia, United Kingdom, New Zealand, Belarus, Bulgaria, Poland, Romania, Estonia, Germany, Sweden, Ukraine, Hungary, Croatia, Georgia, Bosnia and Herzegovina, Latvia, Li... and more
Novartis Pharmaceuticals

Active, not recruiting

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab (ARTIOS)

Relapsing Multiple Sclerosis

United States, Poland, Austria, Belgium, Czechia, Germany, Australia, Switzerland, Lebanon, Argentina, Canada, Slovenia, Bulgaria, Latvia, Russian Federation, Spain, Italy, Turkey, Slovakia, Portugal, Greece, Saudi Arabia, Hungary, No... and more
Hoffmann-La Roche

Active, not recruiting

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis (OLERO)

Multiple Sclerosis

United States, Spain, Austria, Czechia, Italy, Hungary, Australia, Portugal, Serbia, Canada, Germany, United Kingdom, Poland, Romania, Croatia, Israel, Belgium, Bulgaria, Estonia, Switzerland, Mexico, Lithuania, New Zealand, France, Slo... and more
Sanofi

Terminated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta (TERACLES)

Multiple Sclerosis Relapse

Spain, Germany, Sweden, Canada, Austria, Korea, Republic of, Russian Federation, Greece, Hungary, Italy, Belgium, Slovakia, Tunisia, France, Australia, United States, Argentina, Brazil, Chile, Colombia, Denmark, Estonia, Finland, Lith... and more
Novartis

Completed

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

Relapsing Multiple Sclerosis

Germany, Italy, Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, Greece, Hungary, Ireland, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovakia, Spain, Sweden, Switzerland, Turkey, United Kingdom
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

United States, Belgium, Czechia, Russian Federation, Serbia, Spain, Italy, Netherlands, Finland, Estonia, Brazil, France, Germany, Poland, Switzerland, Ukraine, Peru, Argentina, Lithuania, Slovakia, Portugal, Australia, Hungary, Tunisia, Bulgar... and more
Sanofi

Active, not recruiting

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) (GEMINI 2)

Relapsing Multiple Sclerosis

United States, Argentina, Belgium, Brazil, Canada, Chile, Croatia, Czechia, France, Germany, Greece, Hungary, India, Israel, Korea, Republic of, Latvia, Netherlands, Norway, Portugal, Puerto Rico, Russian Federation, Serbia, Slovakia, Spai... and more

Clinical Trials on CNS Malignancies in Portugal

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations